Dr. Gearóid Tuohy

FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)

by Dr. Gearóid Tuohy
25th November 201420th April 2015

SPK-RPE65, a novel gene therapy undergoing development for the treatment of nyctalopia, has received “breakthrough therapy designation” from the FDA. The drug’s sponsor, Spark Therapeutics,… Read More »FDA assigns breakthrough therapy designation to innovative gene therapy approach to nyctalopia (night blindness)

Newly discovered mutation may account for up to 1% of autosomal dominant retinitis pigmentosa (RP)

by Dr. Gearóid Tuohy
25th November 201420th April 2015

Collaborative research, led by the Human Genetics Centre at the University of Texas Health Science Centre in Houston, has successfully described a new genetic mutation… Read More »Newly discovered mutation may account for up to 1% of autosomal dominant retinitis pigmentosa (RP)

« Previous
1
…
68
69
70